Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 11;231(6):1425-1429.
doi: 10.1093/infdis/jiaf098.

Dolutegravir and Risk of Neuropsychiatric Adverse Events: A Pharmacogenetic Study

Julien De Greef  1   2 , Jean Cyr Yombi  2 , Anne Vincent  2 , Bernard Vandercam  2 , Philippe de Timary  3   4 , Lidvine Boland  5 , Magali Philippeau  6 , Nadtha Panin  1 , Laure Elens  1   7 , Vincent Haufroid  1   5 , Leïla Belkhir  1   2
Affiliations

Dolutegravir and Risk of Neuropsychiatric Adverse Events: A Pharmacogenetic Study

Julien De Greef et al. J Infect Dis. .

Abstract

Dolutegravir (DTG) treatment can lead to neuropsychiatric adverse events (NPAEs). This study assessed the association between NPAEs and polymorphisms in DTG-related pharmacogenes, determined by next-generation sequencing panel testing. Using a case-control design, 36 patients having previously discontinued DTG due to NPAEs were compared to 98 patients tolerating DTG. In the latter group, psychometric scores were compared according to genotype, targeting polymorphisms associated with drug intolerance. NR1I2 c.-22-7659C > T was independently associated with a reduced risk of NPAE-related DTG discontinuation (odds ratio, 0.36 [95% confidence interval, .15-.88] for T-variant allele carriage) and was linked to decreased anxiety scores in control group participants.

Keywords: HIV; SLC22A2; UGT1A1; integrase inhibitor; pregnane X receptor.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. J. D. G. has received speaker's fees from ViiV Healthcare and travel support from MSD. B. V. has received speaker's fees from Pfizer, travel support from ViiV Healthcare, and advisory board fees from Pfizer. L. E. holds stocks in Pfizer. L. Be. has received consulting fees from MSD and travel support from GlaxoSmithKline and Gilead Sciences. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.